143 related articles for article (PubMed ID: 10674283)
1. Long-term residual complaints and psychosocial sequelae after remission of hyperthyroidism.
Fahrenfort JJ; Wilterdink AM; van der Veen EA
Psychoneuroendocrinology; 2000 Feb; 25(2):201-11. PubMed ID: 10674283
[TBL] [Abstract][Full Text] [Related]
2. A survey study of neuropsychiatric complaints in patients with Graves' disease.
Stern RA; Robinson B; Thorner AR; Arruda JE; Prohaska ML; Prange AJ
J Neuropsychiatry Clin Neurosci; 1996; 8(2):181-5. PubMed ID: 9081554
[TBL] [Abstract][Full Text] [Related]
3. Quality-of-Life Impairments Persist Six Months After Treatment of Graves' Hyperthyroidism and Toxic Nodular Goiter: A Prospective Cohort Study.
Cramon P; Winther KH; Watt T; Bonnema SJ; Bjorner JB; Ekholm O; Groenvold M; Hegedüs L; Feldt-Rasmussen U; Rasmussen ÅK
Thyroid; 2016 Aug; 26(8):1010-8. PubMed ID: 27370744
[TBL] [Abstract][Full Text] [Related]
4. The relationship between quality of life, cognition, and thyroid status in Graves' disease.
Riguetto CM; Neto AM; Tambascia MA; Zantut-Wittmann DE
Endocrine; 2019 Jan; 63(1):87-93. PubMed ID: 30173328
[TBL] [Abstract][Full Text] [Related]
5. The relationship between mental fatigue, depression, and cognition in Graves' disease.
Johansson B; Holmberg M; Skau S; Malmgren H; Filipsson Nyström H
Eur Thyroid J; 2023 Jul; 12(4):. PubMed ID: 37224080
[TBL] [Abstract][Full Text] [Related]
6. The relationship of psychological factors to the prognosis of hyperthyroidism in antithyroid drug-treated patients with Graves' disease.
Fukao A; Takamatsu J; Murakami Y; Sakane S; Miyauchi A; Kuma K; Hayashi S; Hanafusa T
Clin Endocrinol (Oxf); 2003 May; 58(5):550-5. PubMed ID: 12699435
[TBL] [Abstract][Full Text] [Related]
7. Psychopathological and neuropsychological symptoms in patients with subclinical and remitted hyperthyroidism.
Bommer M; Eversmann T; Pickardt R; Leonhardt A; Naber D
Klin Wochenschr; 1990 Jun; 68(11):552-8. PubMed ID: 2376950
[TBL] [Abstract][Full Text] [Related]
8. Childhood Graves' ophthalmopathy: results of a European questionnaire study.
Krassas GE; Segni M; Wiersinga WM
Eur J Endocrinol; 2005 Oct; 153(4):515-21. PubMed ID: 16189172
[TBL] [Abstract][Full Text] [Related]
9. Age and stress as determinants of the severity of hyperthyroidism caused by Graves' disease in newly diagnosed patients.
Vos XG; Smit N; Endert E; Brosschot JF; Tijssen JG; Wiersinga WM
Eur J Endocrinol; 2009 Feb; 160(2):193-9. PubMed ID: 18974230
[TBL] [Abstract][Full Text] [Related]
10. [The present status of I-131 therapy for Graves' hyperthyroidism in Japan (survey by questionnaire)].
Ikekubo K; Kusakabe K; Kanaya S; Ishikawa N; Nakada K; Mori Y
Kaku Igaku; 2003 Nov; 40(4):457-63. PubMed ID: 14733111
[TBL] [Abstract][Full Text] [Related]
11. Chronic recurrent stress due to panic disorder does not precipitate Graves' disease.
Chiovato L; Marinò M; Perugi G; Fiore E; Montanelli L; Lapi P; Cavaliere R; Ciampi M; Patronelli A; Placidi G; Placidi GF; Cassano GB; Pinchera A
J Endocrinol Invest; 1998 Dec; 21(11):758-64. PubMed ID: 9972676
[TBL] [Abstract][Full Text] [Related]
12. Quality of life, depressive symptoms and anxiety in hyperthyroid patients.
Suwalska A; Lacka K; Lojko D; Rybakowski JK
Rocz Akad Med Bialymst; 2005; 50 Suppl 1():61-3. PubMed ID: 16119629
[TBL] [Abstract][Full Text] [Related]
13. Bone loss in hyperthyroid patients and in former hyperthyroid patients controlled on medical therapy: influence of aetiology and menopause.
Jódar E; Muñoz-Torres M; Escobar-Jiménez F; Quesada-Charneco M; Lund del Castillo JD
Clin Endocrinol (Oxf); 1997 Sep; 47(3):279-85. PubMed ID: 9373448
[TBL] [Abstract][Full Text] [Related]
14. Mood and anxiety disorders in women with treated hyperthyroidism and ophthalmopathy caused by Graves' disease.
Bunevicius R; Velickiene D; Prange AJ
Gen Hosp Psychiatry; 2005; 27(2):133-9. PubMed ID: 15763125
[TBL] [Abstract][Full Text] [Related]
15. Remission of Graves' hyperthyroidism treated with methimazole.
Bolaños F; González-Ortiz M; Durón H; Sánchez C
Rev Invest Clin; 2002; 54(4):307-10. PubMed ID: 12415954
[TBL] [Abstract][Full Text] [Related]
16. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
[TBL] [Abstract][Full Text] [Related]
17. Studies on thyrotrophin receptor antibodies in patients with euthyroid Graves' disease.
Kasagi K; Hatabu H; Tokuda Y; Iida Y; Endo K; Konishi J
Clin Endocrinol (Oxf); 1988 Oct; 29(4):357-66. PubMed ID: 2908031
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of hyperthyroidism caused by Graves' disease or toxic multinodular goitre by radioiodine: over 80% cure retrospectively after one calculated dose].
Bakker SC; Zanin DE; Zweers EJ
Ned Tijdschr Geneeskd; 2002 Sep; 146(39):1837-41. PubMed ID: 12382370
[TBL] [Abstract][Full Text] [Related]
19. Impaired health-related quality of life in Graves' disease. A prospective study.
Elberling TV; Rasmussen AK; Feldt-Rasmussen U; Hørding M; Perrild H; Waldemar G
Eur J Endocrinol; 2004 Nov; 151(5):549-55. PubMed ID: 15538931
[TBL] [Abstract][Full Text] [Related]
20. Regression of the carotid intima media thickness by propylthiouracil therapy in Graves' hyperthyroidism.
Bilir C; Gökosmanoglu F; Caliskan M; Cinemre H; Akdemir R
Am J Med Sci; 2012 Apr; 343(4):273-6. PubMed ID: 21825964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
